TW202112369A - 口服膠囊劑及其製備方法 - Google Patents

口服膠囊劑及其製備方法 Download PDF

Info

Publication number
TW202112369A
TW202112369A TW109119516A TW109119516A TW202112369A TW 202112369 A TW202112369 A TW 202112369A TW 109119516 A TW109119516 A TW 109119516A TW 109119516 A TW109119516 A TW 109119516A TW 202112369 A TW202112369 A TW 202112369A
Authority
TW
Taiwan
Prior art keywords
oral capsule
capsule
rpm
composition
oral
Prior art date
Application number
TW109119516A
Other languages
English (en)
Chinese (zh)
Inventor
王亦平
郭遠靜
Original Assignee
英屬開曼群島商百濟神州有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英屬開曼群島商百濟神州有限公司 filed Critical 英屬開曼群島商百濟神州有限公司
Publication of TW202112369A publication Critical patent/TW202112369A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109119516A 2019-06-10 2020-06-10 口服膠囊劑及其製備方法 TW202112369A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019090543 2019-06-10
WOPCT/CN2019/090543 2019-06-10

Publications (1)

Publication Number Publication Date
TW202112369A true TW202112369A (zh) 2021-04-01

Family

ID=73780902

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109119516A TW202112369A (zh) 2019-06-10 2020-06-10 口服膠囊劑及其製備方法

Country Status (6)

Country Link
US (2) US20220241285A1 (https=)
EP (1) EP3981400A4 (https=)
JP (2) JP2022538215A (https=)
CN (1) CN113950327A (https=)
TW (1) TW202112369A (https=)
WO (1) WO2020249002A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
CN115212115A (zh) * 2021-09-27 2022-10-21 百济神州(苏州)生物科技有限公司 泽布替尼的鼻饲给药
CN119699478B (zh) * 2024-12-24 2025-12-12 衡睿(广东)生物科技有限公司 一种高油脂含量的胶囊制剂及其制备方法
CN119818691B (zh) * 2025-03-18 2025-08-05 宁波美诺华天康药业有限公司 一种含有伊布替尼的药物组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902686C (en) * 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2018033853A2 (en) * 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN112165939A (zh) * 2018-03-21 2021-01-01 梅制药公司 联合疗法
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Also Published As

Publication number Publication date
JP2025123534A (ja) 2025-08-22
WO2020249002A1 (zh) 2020-12-17
CN113950327A (zh) 2022-01-18
EP3981400A4 (en) 2023-07-12
US20220241285A1 (en) 2022-08-04
US20230149411A1 (en) 2023-05-18
JP2022538215A (ja) 2022-09-01
EP3981400A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
TW202112369A (zh) 口服膠囊劑及其製備方法
JP7550393B2 (ja) 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
JP6876758B2 (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
US12233069B2 (en) Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor
CN116157391A (zh) 包含egfr抑制剂的药物组合物及其制备方法
CN112220770B (zh) 司来帕格的药物组合物及其制备方法
CN112472675B (zh) 司来帕格片剂及其制备方法
EP2902015B1 (en) Preparation method of agomelatine solid preparation
TWI844581B (zh) 呋喹替尼製劑及其應用
CN103251569B (zh) 卡培他滨片组合物及其制备方法
CN110769825B (zh) 一种含有喹啉衍生物的药物组合物
CN112057432A (zh) 口服胶囊剂及其制备方法
HK40066903A (en) Oral capsule and preparation method therefor
WO2022062096A1 (zh) 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
HK1243357A1 (zh) 一种含有喹啉衍生物或其盐的药物组合物的制备方法
TWI896159B (zh) 一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
CN108078945B (zh) 卡格列净药物组合物
CN117919186A (zh) 一种甲磺酸沙芬酰胺片及其制备方法
CN109674759A (zh) 一种达泊西汀药物组合物及其制备方法
HK40062459A (en) Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
CN121846036A (zh) 一种艾瑞昔布固体制剂及其制备方法
CN119745892A (zh) 含有别孕烷醇酮衍生物的药物组合物及其用途
CN104208033A (zh) 一种晶ⅰ型阿戈美拉汀片剂及其制备工艺